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A b s t r a c t
Introduction: Barrett’s oesophagus (BE) is a columnar metaplasia caused by chronic gastroesophageal reflux
associated with increased risk of developing adenocarcinoma. There are three main goals of treatment for BE – to
provide control of reflux syndrome, eradication of metaplastic tissue, and to provide a new antireflux barrier for long-
term pH stabilization. Ablative therapy with argon plasma coagulation in BE patients leads to removal of metaplastic
and dysplastic cells.
Aim: To determine in a prospective study the efficacy of endoscopic argon plasma coagulation (APC) in combination
with proton pump inhibitors (PPIs) for ablation of Barrett’s oesophagus with or without low grade dysplasia. 
Material and methods: Between January 2005 and December 2008, thirty patients (19 men, 11 women; mean age 54.9
years) with histologically proven BE were treated with APC in combination with 80 mg/day pantoprazole. All patients
underwent endoscopy at 12 months.
Results: After 12 months, 22 of 30 patients (73.3%) had complete regression of Barrett’s oesophagus. Regeneration of
squamous epithelium was observed after a median of 1.78 sessions (range: 1 to 4). The number of sessions depends
on the extent and histological type of metaplasia. 
Conclusions: Argon plasma coagulation offers a safe, minimally invasive method, which gave complete regression of
metaplasia and low grade dysplasia usually in more than 70% of patients with Barrett’s oesophagus. Our results show
that combination of APC and PPIs is an effective treatment option for most patients with BE.
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Introduction
Barrett’s oesophagus (BE) is a condition in which
the mucosa, due to chronic irritation with gastric or
gastro-duodenal content, undergoes adaptive rear-
rangement with columnar cells’ proliferation pushing
the Z line away from the upper margin of the gastric
folds. Barrett’s oesophagus is considered to be 
a precancerous state, due to increased risk of
adenocarcinoma in these patients. Risk of dysplasia
in patients with BE varies from 2 to 25%, according to
different sources. Adenocarcinoma of the oeso-
phagus develops in 0.5-1% of cases.
The opinion that glandular metaplasia of the
gastroesophageal junction and risk of adenocarcinoma
of the oesophagus are closely correlated is commonly
accepted, yet mechanisms of this relation have not
been completely understood. Establishing connections
of these phenomena is essential to define groups of
patients at risk of oesophageal adenocarcinoma.
Treatment of BE patients involves both methods
typically applied in non-complicated GERD and 
BE-specific techniques [1, 2]. The ultimate goal of
treatment of BE patients is to control symptoms of
reflux disease, remove tissues at risk of adeno-
Videosurgery
Videosurgery and other miniinvasive techniques 2009; 4/3 103
carcinoma development, and finally, effective pre-
vention of reflux content from contacting mucosa of
the distal oesophagus. Hence, pharmacological
therapy ought to be supplemented with endoscopic
methods. An aim of endoscopic ablation is to destroy
both Barrett’s epithelium and any dysplasia present,
allowing for squamous re-epithelialization. The most
popular methods include: argon plasma coagulation
(APC), laser thermoablation, photo-dynamic therapy
(PDT), and multipolar electro-coagulation (MPEC).
Aim
The goal of this study was to establish a diag-
nostic and therapeutic APC-based algorithm for
patients with BE without high-grade dysplasia and to
assess the efficacy of metaplastic lower oesophagus
mucosa destruction with argon plasma ablation. 
Material and methods
Thirty patients with histologically confirmed
Barrett’s oesophagus, treated in the 2nd Department
of General Surgery of the Jagiellonian University
Collegium Medicum between January 2005 and
December 2008 were included in the study. Follow-up
time of each and every patient was 12 months from
complete removal of columnar metaplasia. The group
included 19 men and 11 women. Average age was
54.9 years, respectively in women 55.3 and in men
54.6 years. Mean length of circumferential extent 
(C extent) was 1.2 cm and maximal 3 cm. Maximum
reach of Barrett’s epithelium (M extent) was 5 cm
and mean 3.06 cm. In the majority of patients,
metaplastic epithelium could be found in more than
one quadrant of the oesophagus (Figure 1). Two 
(12 patients, 40%) or just one (10 – 33.3% of patients)
quadrant involvement prevailed. 
Foci of glandular metaplasia were found most
often within the 2nd quadrant of the oesophagus 
(21 patients). Barrett’s oesophagus was found in the
1st quadrant in 17 patients and in 15 patients in
quadrant 3. Involvement of the 4th quadrant was the
least common (Figure 2).
Three types of columnar metaplasia were found
in the analyzed group (Figure 3). Patients with
complete intestinal metaplasia without dysplasia 
(21-70% of patients) prevailed, with incomplete
intestinal metaplasia without dysplasia seen in 
4 patients (13%) and complete dysplasia in 5 (17%).
Low-grade dysplasia was present in 3 and
moderate in 2 of 30 patients from the analyzed
group. In 17% Helicobacter pylori infection was seen
and treated with the standard eradication scheme.
Every patient qualified for this research pro-
gramme had baseline gastroscopy performed for
macroscopic assessment of lesions in mucosa of
the distal oesophagus, sampling biopsy specimens
for histology and rapid urease test for H. pylori.
Proximal shift of Z line was diagnostic of
endoscopically suspected oesophageal metaplasia
(ESEM), and hence raised suspicion of columnar
metaplasia of the oesophagus. Biopsies were taken
from 4 quadrants of the oesophagus at 1 cm
intervals due to the patchy nature of BE disease
and the need for accurate localization of the
metaplasia foci before ablative treatment. On the
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Figure 1. Number of quadrants of the oeso-
phagus affected with columnar metaplasia prior
to treatment
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Figure 2. Involvement of individual quadrants 
of the lower oesophagus with columnar meta-
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same occasion, the extent of metaplasia was
assessed according to the widely accepted Prague
criteria, i.e. C and M. In this system measurement is
done with accuracy of 1 cm of circumferential
extent (C) and maximum extent (M) of metaplastic
inserts within mucosa. Results are shown as CxMy,
where x and y are respective mea-surement true
values [3].
Basic inclusion criteria were: presence of
glandular cells in the distal oesophagus in baseline
histology and informed consent of the patient.
After metaplasia had been confirmed, patients
underwent argon plasma ablation in affected
quadrants. The procedure was accomplished with
ERBOTOM ICC 350 electrosurgical diathermy with
argon APC 300 add-on and flexible coagulation
probe with front lumen. Power was adjusted at 
60 W with argon flow of 1.8 l/min. Most of the
patients were hospitalized until the following day.
During one session, no more than 2 quadrants
were treated with argon plasma ablation. When
metaplasia extended into 3 or 4 quadrants, the
procedure was repeated after 4-6 weeks. The first
endoscopic control with biopsy was performed 
6 weeks following the final ablation procedure.
During the whole treatment period patients were
administered 40 mg pantoprazole bid. When
cylindrical epithelium was still present in the
oesophageal mucosa during control endoscopy, the
whole procedure was repeated until the desired
effect was attained. The next control endoscopy
was done 12 months after completion of ablative
treatment.
Results
No complications of the applied treatment were
seen in any of the patients. Combination of PPI and
endoscopic argon beam ablation was well tolerated.
During the whole study period no side-effects of the
treatment were seen. There was no need to stop the
therapy in any of the treated patients.
Effectiveness of endoscopic ablation procedures
was dependant on the extent of mucosal lesions and
the initial type of columnar metaplasia. Mean
number of argon ablation sessions needed to obtain
re-epithelialization with squamous cells was
proportional to the circumferential extent of meta-
plasia – C feature of Prague classification (Figure 4).
In patients with BE manifested by only an inset of
metaplastic epithelium (C0 in Prague classification)
mean number of coagulation sessions per patient
was 1.22. When height of the circumferential
segment was 3 cm, it was necessary to perform 
2.25 ablation procedures to end up with re-
epithelialization with squamous cells (Figure 4).
A similar relation was found with maximum extent
(measured in cm) of Barrett’s epithelium (M feature of
the Prague criteria) and the number of necessary
argon ablations (Figure 5). Patients with the smallest,
i.e. 2 cm, extent of metaplasia needed on average 1.33
coagulation sessions to attain planocellular re-
epithelialization. In patients with the maximal extent
seen in the group (5 cm), the number of APCs needed
increased more than twofold (Figure 5).
Significant reduction of columnar metaplasia in







Figure 4. Mean number of ablation sessions
with argon plasma needed to obtain squamous
cell re-epithelialization in correlation to circum-
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after argon plasma during 12-month follow-up.
Highest efficacy of ablation was achieved for
quadrants 3 and 2, yet the difference was not
significant (Figure 6).
Average efficacy of argon plasma coagulation in
combination with 80 mg pantoprazole, regardless of
the extent of pathological lesions, allowed complete
squamous re-epithelialization to be obtained and
maintained in more than 78% of patients (Table I).
A difference in argon plasma coagulation efficacy
in various types of metaplasia was found in the
analyzed group of patients. Only patients with
incomplete intestinal metaplasia could enjoy com-
plete, i.e. 100%, efficacy of APC (Figure 7). Mean ef-
fectiveness of this therapeutic method in all types of
metaplasia was 73.3% (Table II).
Based on these results, the following conclusions
were formulated:
• argon plasma ablation results in efficient removal of
metaplastic epithelium in patients with Barrett’s
oesophagus,
• combination of ablation therapy and anti-secretory
pharmacotherapy with above-standard dosage of
PPIs allows planocellular reepi-thelialization to be
established in almost 80% of patients – the
technique of argon plasma ablation at normalized
pH in the lower oesophagus is a safe and highly
efficient method,
• effectiveness of ablation depends on the extent and
histological grade of columnar metaplasia,
• perfection of endoscopic ablation techniques in the
future can reduce the risk of adenocarcinoma of the
oesophagus from Barrett’s oesophagus.
Discussion
Mucosal lesions now classified as Barrett’s
oesophagus were described as early as the beginning
of the 19th century. In the first place, peptic ulcers of
the oesophagus drew attention. The oesophagus was
lined with mucosa morphologically not different from
gastric mucosa. In 1950 Norman Barrett described this
condition in “Chronic peptic ulcer of the oesophagus
and oesophagitis”, which he believed was 
a complication of inflammation of the gastric mucosa
shifted into the thorax. The disease was thought to
result from congenital shortening of the oesophagus.
In 1953 Allison and Johnston in their studies
confirmed that, unlike the stomach, the affected part








Figure 5. Mean number of argon plasma
ablation sessions necessary for planocellular re-
epithelialization in regard to maximum length

































Number of oesophageal quadrant
I II III IV




















Figure 7. Efficacy of argon plasma ablation in
different types of columnar metaplasia
MJ (+) – complete intestinal metaplasia without dysplasia
MJ (–) – incomplete intestinal metaplasia without dysplasia
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Figure 6. Efficacy of argon plasma coagulation
(APC) in each quadrant of the oesophagus
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wall has a structure typical for the oesophagus.
Hence, Barrett’s earlier theory proved false.
The true turning point in the concept of reflux
disease and Barrett’s oesophagus were theses
published at the end of 2006 as the so-called
Montreal consensus. In this collection of experts’
opinions, contemporary knowledge on Barrett’s
oesophagus was summarized in 9 points [4]. The
quoted consensus once more underlined strict
correlation of columnar metaplasia with oesophageal
adenocarcinoma development. Presence of a pre-
cancerous condition (which Barrett’s oesophagus
really is) determines the need for treatment in this
group of patients. No universal therapeutic algorithm
has been developed so far. What is more, the
contradictory notions on the effectiveness of various
techniques often met in the literature make figuring
out such an algorithm even less likely. Most authors
emphasize the efficacy of endoscopic ablative
procedures in supplementation of anti-secretory
pharmacotherapy in patients with BE.
APC technique has been broadly applied in
endoscopic treatment of many GI tract pathologies.
Classical application of this method is to control
haemorrhage, especially from non-resectable
malignant tumours. Argon plasma coagulation is
also used for destruction of pathological tissue,
both in curative and palliative treatment. In
patients with Barrett’s oesophagus APC technique
is used to ablate foci of metaplasia with controlled
coagulation. A monopolar no-touch electrode
spreads high frequency electric current in an argon
sheath. The result of the procedure is coagulation of
tissue at a depth limited to 1-3 mm. Depth of
penetration depends on the generated power (range:
0-155 W), argon flow (range: 0.5-7 l/min), distance
from electrode to tissue (range: 2-8 mm) and
application time (0.5-2 s or continuous ablation). In
ablation of Barrett’s metaplasia power of 30-90 W is
used with argon flow of 1-2 l/min [5]. The procedure
is usually conducted under intravenous sedation with
benzodiazepines. 
APC technique remains the best studied and 
a commonly accepted method of endoscopic ablation
of metaplasia in oesophageal mucosa in patients
without dysplasia [5]. The popularity of this method
stems from its ease of application. The low cost of
APC must also be considered. In the department
where the study was conducted the device was used
for other therapeutic purposes than treatment of BE
patients. Ablation of metaplasia in BE with argon
plasma is a safe procedure with efficacy approaching
90% and is not inferior to photodynamic technique
[6]. Complications after this method are rare and not
Affected quadrant of the oesophagus Prior to treatment After treatment and follow-up Efficacy [%]
1 17 6 64.7
2 21 2 90.5
3 15 1 93.3
4 11 4 63.6
Mean 78.1%
Table I. Efficacy of argon plasma ablation according to the extent of metaplasia 
Table II. Efficacy of argon plasma ablation in different types of columnar metaplasia 
Histological type Initial number of patients Number of patients with residual metaplasia APC efficacy [%]
Complete intestinal 21 5 76.2
metaplasia MJ (+)
Incomplete intestinal 4 0 100
metaplasia MJ (–)
Complete intestinal 5 3 40
metaplasia with 
dysplasia MJ (+) D
average 73.3
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life-threatening in the majority of cases. Typical
complications include chest pain and odynophagia.
Stricture, haemorrhage and perforation of the
oesophagus that can lead to mediastinitis and,
eventually, to the patient’s death are severe
complications [7, 8]. Only two deaths directly at-
tributable to iatrogenic oesophagus injury during
argon plasma ablation have been described in the
literature. Notions of microperforation with pleural
effusion and fever are more frequent [9]. 
In our group of 30 patients procedures were
conducted with an argon beam coagulator.
Squamous re-epithelialization was preserved for 
12 months in 22 patients (73.3%). Our results are
similar to data found in the literature, where a similar
effect was observed in 68-100% of argon plasma
ablation cases [10]. As in Morris and Madisch’s
studies including respectively 173 and 280 patients in
our study no dysplasia or adenocarcinoma developed
during 12-month follow-up [7].
The described ablative technique, although very
efficient, does not permanently prevent recurrence of
Barrett’s metaplasia, when the oesophagus is
constantly exposed to reflux content. Anti-secretory
therapy with PPIs causes temporary pH norma-
lization when acidic reflux dominates. In non-acidic
reflux the effectiveness of such treatment obviously
falls. Another negative feature of long-term PPI
therapy is the fact that in patients with Helicobacter
pylori infection it can cause spreading of infection to
the stomach body, causing atrophic gastritis [11]. 
A way to achieve lasting pH normalization 
is permanent treatment with anti-secretory
pharmacotherapy or surgical correction of the anti-
reflux mechanism. In Basu’s studies a higher
percentage of metaplasia recurrence was seen in
patients on reduced PPIs dose, which indicates the
need for above-standard dosage [10].
Rules of qualification of patients with BE with-
out high grade dysplasia for treatment remain
controversial. In the analyzed group of patients the
maximum extent of metaplasia was 5 cm with
mean of 3.06 cm. In Dulai’s study 24 patients with
BE and mean length of metaplasia of 4 cm and
neither high grade dysplasia nor cancer were
subjected to argon ablation supplemented with 
80 mg/day pantoprazole [12]. In 35% of these
patients residual Barrett’s metaplasia could be
found, which is not much different from our result.
The quoted analysis indicates higher therapeutic
value of APC technique when compared to the
other popular method of ablation, multipolar
electrocoagulation (MPEC). The simplicity of the
former method is another argument to use it.
According to the literature, more than one ablation
session is usually necessary to completely remove
columnar metaplasia and achieve squamous re-
epithelialization of the oesophagus [9, 13]. For
successful ablation of metaplastic mucosa of the
gastroesophageal junction, and hence squamous re-
epithelialization, two to five ablation sessions are
usually needed. According to some authors, a single
procedure with the argon beam coagulator results
in complete removal of pathological tissue in 55-
100% of cases. In our study, 1.78 ablation procedures
were done per patient. The number of sessions
depended on the extent of metaplasia. Patients
with 2 cm extent of Barrett’s epithelium (M feature
in the Prague criteria) on average required 1.33
procedures, while those with the greatest (5 cm)
extent needed twice as many APC sessions. Circular
extent (C feature) of metaplasia proved no less
important. In patients with lesions affecting a single
column (C = 0) the average number of APC sessions
was 1.22. In patients with the largest, 3-cm circular
extent a mean of 2.25 ablations of metaplastic
mucosa were conducted. Another factor affecting
the number of necessary ablation sessions was
histological type of columnar metaplasia. In the
most numerous group of patients with complete
columnar metaplasia without dysplasia, the average
number of procedures needed was 1.72, which is
comparable to data from other authors [9, 14]. In
patients with incomplete intestinal metaplasia this
number was 1.5 sessions. In patients with complete
intestinal metaplasia with low or middle grade
dysplasia, the number of required sessions
increased to 2. These results show an influence of
the initial grade of histological changes within the
BE mucosa on the course of ablative treatment. 
The possibility of overlooking foci of metaplasia 
in deeper layers of the oesophageal wall is anoth-
er disadvantage of the method described in the
literature. Yet destruction of the main mass of
pathological tissue is believed to bring about 
a wipeout to the bulk of aberrant DNA, which
significantly reduces the risk of malignancy [15]. In
spite of the notions of development of oesophageal
adenocarcinoma in patients with BE after APC
treatment, large cohort studies clearly show that the
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described thermoablation method has more
advantages than drawbacks [16].
The efficacy of argon thermoablation is believed
to increase proportionally to the power of coagulation
[9]. Such modification combined with high dose PPI
increases both the effectiveness of the method and
the risk of severe complications, especially per-
foration of the oesophagus wall. We used fixed 60 W
power of argon ablation and did not observe any
complications during 12-month follow-up. Schultz
applied 90 W argon ablation with 120 mg of
omeprazole a day. After mean follow-up of 12 months
no Barrett’s metaplasia was detected in 69 of 70
patients (98.6%) [13]. An average of 2 APC sessions
were done (range: 1-5). In this study, stricture of the
oesophagus was found in 3 patients and was
successfully treated with a single endoscopic balloon
dilatation procedure. According to numerous authors,
application of high-power ablation brings about
similarly satisfactory long-term results, and the latest
publications prove the reduced risk of the method,
which is attributable to increasing experience of the
centre [17]. Thus, application of high-power ablation
in selected, refractory cases of Barrett’s metaplasia
seems reasonable, yet one must not forget the
growing risk of complications.
In some patients after argon plasma ablation
cylindrical cells are found during control biopsy. In our
study it occurred in 8 patients. No dysplasia or cancer
was seen. There were unique cases of oesophageal
adenocarcinoma described to rise from Barrett’s
metaplasia located beneath the layer of post-ablation
squamous re-epithelialization [4, 16]. Presence of
residual metaplasia can be explained by two theories.
The first one indicates too shallow penetration of
ablation energy into the oesophageal wall. According
to the other, patchy metaplasia contributes to
incorrect assessment of extent and identification of
Barrett’s epithelium foci, which leads to exclusion of
this area from being biopsied. Limited reliability of
macroscopic diagnosis of metaplasia of the gastro-
oesophageal junction in classic endoscopy is of
clinical importance. 
Barrett’s oesophagus is a late complication of
reflux disease. Pharmacological treatment tem-
porarily improves pH of the gastro-oesophageal
junction without regulating efficiency of the physio-
logical anti-reflux barrier. In patients subjected to
ablation of metaplastic mucosa, it is necessary to
tailor the influence of regurgitated gastric content on
the oesophagus in the long run to maintain the
therapeutic effect of squamous re-epithelialization.
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